Combining mutations in HIV‐1 protease to understand mechanisms of resistance

HIV‐1 develops resistance to protease inhibitors predominantly by selecting mutations in the protease gene. Studies of resistant mutants of HIV‐1 protease with single amino acid substitutions have shown a range of independent effects on specificity, inhibition, and stability. Four double mutants, K45I/L90M, K45I/V82S, D30N/V82S, and N88D/L90M were selected for analysis on the basis of observations of increased or decreased stability or enzymatic activity for the respective single mutants. The double mutants were assayed for catalysis, inhibition, and stability. Crystal structures were analyzed for the double mutants at resolutions of 2.2–1.2 Å to determine the associated molecular changes. Sequence‐dependent changes in protease‐inhibitor interactions were observed in the crystal structures. Mutations D30N, K45I, and V82S showed altered interactions with inhibitor residues at P2/P2′, P3/P3′/P4/P4′, and P1/P1′, respectively. One of the conformations of Met90 in K45I/L90M has an unfavorably close contact with the carbonyl oxygen of Asp25, as observed previously in the L90M single mutant. The observed catalytic efficiency and inhibition for the double mutants depended on the specific substrate or inhibitor. In particular, large variation in cleavage of p6pol‐PR substrate was observed, which is likely to result in defects in the maturation of the protease from the Gag‐Pol precursor and hence viral replication. Three of the double mutants showed values for stability that were intermediate between the values observed for the respective single mutants. D30N/V82S mutant showed lower stability than either of the two individual mutations, which is possibly due to concerted changes in the central P2‐P2′ and S2‐S2′ sites. The complex effects of combining mutations are discussed. Proteins 2002;48:107–116. © 2002 Wiley‐Liss, Inc.

[1]  J. Louis,et al.  Structural implications of drug‐resistant mutants of HIV‐1 protease: High‐resolution crystal structures of the mutant protease/substrate analogue complexes , 2001, Proteins.

[2]  P. Harrigan,et al.  Human Immunodeficiency Virus Type 1 Protease Cleavage Site Mutations Associated with Protease Inhibitor Cross-Resistance Selected by Indinavir, Ritonavir, and/or Saquinavir , 2001, Journal of Virology.

[3]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[4]  T. Merigan,et al.  Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients , 1998, Annals of Internal Medicine.

[5]  R. Stroud,et al.  Structure of the protease from simian immunodeficiency virus: complex with an irreversible nonpeptide inhibitor. , 1993, Biochemistry.

[6]  G. Cohen Align : A program to superimpose protein coordinates, accounting for insertions and deletions , 1997 .

[7]  G. Sheldrick,et al.  SHELXL: high-resolution refinement. , 1997, Methods in enzymology.

[8]  G. Marius Clore,et al.  Autoprocessing of HIV-1 protease is tightly coupled to protein folding , 1999, Nature Structural Biology.

[9]  D. Ho,et al.  Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.

[10]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[11]  J. Louis,et al.  Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease. , 1998, Biochemistry.

[12]  P. Massip,et al.  Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV‐1 infection , 2000, Journal of medical virology.

[13]  V. Trouplin,et al.  Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug , 2000, Journal of Virology.

[14]  Brendan A. Larder,et al.  Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples , 2000, AIDS.

[15]  B. Korber,et al.  HIV sequence compendium 2002 , 2002 .

[16]  Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates. , 1997, European journal of biochemistry.

[17]  M. Sternberg,et al.  An analysis of conformational changes on protein-protein association: implications for predictive docking. , 1999, Protein engineering.

[18]  J. Louis,et al.  Structural basis for specificity of retroviral proteases. , 1998, Biochemistry.

[19]  H. Kräusslich,et al.  Cleavage of Human Immunodeficiency Virus Type 1 Proteinase from the N-Terminally Adjacent p6* Protein Is Essential for Efficient Gag Polyprotein Processing and Viral Infectivity , 1998, Journal of Virology.

[20]  R. Zahler Enzyme Structure and Mechanism , 1979, The Yale Journal of Biology and Medicine.

[21]  Martine Peeters,et al.  Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients , 2000, Journal of Clinical Microbiology.

[22]  A Wlodawer,et al.  Programming the Rous Sarcoma Virus Protease to Cleave New Substrate Sequences (*) , 1996, The Journal of Biological Chemistry.

[23]  F. Mammano,et al.  Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.

[24]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[25]  L Hong,et al.  Crystal structure of an in vivo HIV‐1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance , 2000, Protein science : a publication of the Protein Society.

[26]  A Wlodawer,et al.  Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. , 1998, Biochemistry.

[27]  J. Martinez-Picado,et al.  Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.

[28]  B. Larder,et al.  Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .

[29]  Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates. , 1997 .

[30]  A Wlodawer,et al.  Human Immunodeficiency Virus, Type 1 Protease Substrate Specificity Is Limited by Interactions between Substrate Amino Acids Bound in Adjacent Enzyme Subsites (*) , 1996, The Journal of Biological Chemistry.

[31]  S. Gulnik,et al.  Drug resistance mutations can affect dimer stability of HIV‐1 protease at neutral pH , 1999, Protein science : a publication of the Protein Society.

[32]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[33]  J. Louis,et al.  Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. , 1996, Biochemistry.

[34]  T. Schneider,et al.  Objective comparison of protein structures: error-scaled difference distance matrices. , 2000, Acta crystallographica. Section D, Biological crystallography.

[35]  J. Louis,et al.  Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. , 2000, European journal of biochemistry.

[36]  Irene T. Weber,et al.  Studies on the Symmetry and Sequence Context Dependence of the HIV-1 Proteinase Specificity* , 1997, The Journal of Biological Chemistry.

[37]  Axel T. Brunger,et al.  X-PLOR Version 3.1: A System for X-ray Crystallography and NMR , 1992 .

[38]  J S Sack,et al.  CHAIN: a crystallographic modeling program. , 1997, Methods in enzymology.

[39]  A. Kaplan,et al.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions , 1994, Journal of virology.